Affordable Access

deepdyve-link
Publisher Website

Estimated medical cost reductions associated with apixaban in real-world patients with non-valvular atrial fibrillation.

Authors
  • Amin, Alpesh
  • Stokes, Michael
  • Wu, Ning
  • Gatt, Elyse
  • Makenbaeva, Dinara
  • Wiederkehr, Daniel
  • Boulanger, Luke
Type
Published Article
Journal
Journal of medical economics
Publication Date
Oct 01, 2013
Volume
16
Issue
10
Pages
1193–1202
Identifiers
DOI: 10.3111/13696998.2013.828064
PMID: 23883416
Source
Medline
License
Unknown

Abstract

If RRRs demonstrated in ARISTOTLE persist in RW, the use of apixaban will be associated with lower medical costs vs warfarin. Main limitations of this study were: identification of clinical events using administrative codes rather than confirmatory clinical data, inability to evaluate the level of international normalized ratio (INR) control, and not including INR monitoring and drug costs.

Report this publication

Statistics

Seen <100 times